The Mucolipidosis type IV face: When the Clinician`s Observation Meets Facial Recognition Technology

בן פודה-שקד 1,2,3 Yonit Banet-Levi 1 Nicole Fleischer 4 Lior Wolf 4,5 Yael Finezilber 1 Lior Greenbaum 1,3 Shiri Liber 1,3 Annick Raas-Rothschild 1,3
1The Institute for Rare Diseases, The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer
2The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer
3Sackler Faculty of Medicine, Tel-Aviv University
4FDNA Inc, FDNA Inc
5Department of Computer Sciences, Tel-Aviv University

Background: Mucolipidosis type IV (ML-IV) is a rare autosomal recessive lysosomal storage disease, caused by mutations in the MCOLN1 gene. It manifests with non-specific symptoms of developmental delay, esotropia and even corneal clouding. While the clinical phenotype, molecular basis and underlying pathomechanism have been described, the diagnosis of ML-IV remains elusive and patients are often misdiagnosed. Our clinical observation was that ML IV patients share common and identifiable facial features, which have yet to be included in the clinical phenotype as described in the literature to date.

Objective and methods: In order to validate these findings using an objective and digital tool, two-dimensional facial images of ten patients with ML-IV, obtained at various ages, were analyzed using facial dysmorphology novel analysis (FDNA). This technology utilizes various measurements extracted from automatically-detected facial points from facial photographs, to recognize distinct dysmorphic features and analyze their similarities to known facial patterns, termed gestalts.

Results: When analyzed in comparison to a control cohort of unaffected cases (n=100) and a cohort of cases diagnosed with syndromes other than ML-IV (n=100), the ML-IV cohort showed a mean area-under-the-curve (AUC) of 0.77 (SD, 0.19) and 0.87 (SD, 0.05), respectively.

Conclusions: We describe for the first time recognizable facial features typical in patients with ML-IV. Reaffirmed by the objective FDNA technology, the described common facial gestalt adds to the tools currently available for clinicians and may thus assist in reaching an earlier diagnosis of this rare and underdiagnosed disorder.

בן פודה-שקד
בן פודה-שקד
Sheba Medical Center








Powered by Eventact EMS